Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature
Pediatric Dermatology2018Vol. 35(5), pp. e286–e290
Citations Over TimeTop 13% of 2018 papers
Abstract
The mTOR inhibitor rapamycin is used systemically for the treatment of vascular lesions. We report the first use of topical rapamycin for the successful treatment of two cases of tufted angioma. The evidence for the use of topical rapamycin in other dermatologic conditions is summarized to aid in clinical decision making on preparations and anticipated side effects.
Related Papers
- → Treatment of childhood kaposiform hemangioendothelioma with sirolimus(2010)151 cited
- → Achieving cancer cell death with PI3K/mTOR‐targeted therapies(2013)27 cited
- → Topical rapamycin (sirolimus) for the treatment of uncomplicated tufted angiomas in two children and review of the literature(2018)12 cited
- → EFFECT OF MTOR INHIBITOR ON DYSLIPIDEMIA IN HEART TRANSPLANT RECIPIENTS RECEIVING STATINS. IS THERE ANY DIFFERENCE BETWEEN SIROLIMUS AND EVEROLIMUS?(2008)
- → POS-794 Conversion to sirolimus in kidney transplant patients: the main indications(2022)